News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

20.10.2011 | 111020_Save_the_date_english

Media briefing to take place at UEGW, Stockholm, Sweden, 25th October 2011

Berlin, Germany, and Seattle, WA, USA

Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today announced that it will hold a briefing on the European launch of its second generation colorectal cancer test, Epi proColon® 2.0 CE, at the United European Gastroenterology Week (UEGW) in Stockholm, Sweden.

Media are invited to join the company for a press briefing at the UEGW on Tuesday, October 25, 2011 at 10:35 am CET at booth A13:34 in Hall A, Stockholmsmässan, Mässvägen 1, Älvsjö, 125 80 Stockholm, Sweden. The briefing will include the following presentations:

  • Dr. Gunter Weiss, Epigenomics’ Vice President Product Development will give an overview on the development and technical improvements of Epi proColon®2.0 CE.
  • Dr. med. Juergen Beck, Senior Vice President Medical Affairs will point out the clinical advantages of the new Epi proColon® 2.0 CE Assay.
  • An open discussion afterwards allows enough time for the plenum to ask questions.

Interested parties not present at UEGW can follow the presentations and contribute to the discussion in an audio webcast. The dial-in numbers for the conference call are:

Dial-in number (within Germany): +49 30 86871428

Dial-in number (within the UK): +44 203 3679216

Participants are kindly requested to dial in 10 minutes prior to the start of the
call.

The presentation accompanying the conference call and dial-in details for the audio webcast will be available on our website at http://www.epigenomics.com/en/news-investors.html

A webcast of the conference call will be provided on Epigenomics’ website subsequently: http://www.epigenomics.com/en/news-investors.html

Epi proColon® 2.0 CE not only has a significantly enhanced performance over the first generation Epi proColon® test, but it also features a number of other improvements that should facilitate its use for diagnostic routine in different regulatory environments including the U.S. For example, results using Epi proColon®2.0 CE can be obtained within a typical laboratory work shift of 8 hours. By contrast, the first generation test took two days of laboratory work. Further adaptations include the use of cGMP manufactured reagents, simplified handling and improved automation capabilities. 

Contact Epigenomics AG

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.